Last reviewed · How we verify

NCT05380908

Brain Metabolic Network of PET in Patients With Advanced Non-Small Cell Lung Cancer

Completed Last updated 19 May 2022
What this trial tests

trial testing None of any intervention in Advanced Non-small-cell Lung Cancer in 90 participants. Completed in 28 February 2021.

Timeline
1 June 2017
Primary endpoint
28 February 2021
28 February 2021

Quick facts

Lead sponsorFifth Affiliated Hospital, Sun Yat-Sen University
StatusCompleted
Study typeOBSERVATIONAL
Enrollment90
Start date1 June 2017
Primary completion28 February 2021
Estimated completion28 February 2021
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Fifth Affiliated Hospital, Sun Yat-Sen University

Who can join

Eligibility, any sex, with Advanced Non-small-cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is a retrospective study, screening patients with systemic PET / CT scan in our department, enrolling the ones who meet the criteria, collect their information and resting state brain PET images.Then make the brain metabolic network analysis and statistical analysis to explore the PET brain metabolic network of non-small cell lung cancer patients and the effect of chemotherapy drugs on brain metabolic network in patients with advanced lung cancer.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Advanced Non-small-cell Lung Cancer

Currently open trials in the same condition.

Other Fifth Affiliated Hospital, Sun Yat-Sen University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05380908.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing